CRO league tables: Competition, privatization and acquisition
This article was originally published in Scrip
Over the past 12 months, the CRO industry has continued to make its mark in drug development. The IPO of the largest player in the market and the merger of two competitor companies are just two of the brushstrokes that make up the CRO portrait to date. Jo Shorthouse steps back and takes in the view.